GSK, J&J Plan Filings For Third-To-Market IL-6 Inhibitor Sirukumab

GlaxoSmithKline PLC and Janssen Biologics, a Johnson & Johnson subsidiary, will seek regulatory approvals for sirukumab in 2016 based on positive Phase III results in rheumatoid arthritis, setting the biologic up to compete with two other interleukin-6 (IL-6) inhibitors when it hits the market in 2017.